Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience | Zendy

Giuseppiovo | Zendy; Daniela Di Lisi | Zendy; Enrico Bronte | Zendy; Francesca Macaione | Zendy; Vincenzo Accurso | Zendy; Giuseppe Badalamenti | Zendy; Gaetana Rinaldi | Zendy; Sergio Siragusa | Zendy; Salvatore Novo | Zendy; Antonio Russo | Zendy

Open Access

Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience

Author(s) -

Giuseppiovo,

Daniela Di Lisi,

Enrico Bronte,

Francesca Macaione,

Vincenzo Accurso,

Giuseppe Badalamenti,

Gaetana Rinaldi,

Sergio Siragusa,

Salvatore Novo,

Antonio Russo

Publication year - 2020

Publication title -

oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.987

H-Index - 98

eISSN - 1423-0232

pISSN - 0030-2414

DOI - 10.1159/000505486

Subject(s) - medicine , cardiology , nilotinib , dasatinib , adverse effect , pulse wave velocity , cancer , coronary artery disease , imatinib , surgery , blood pressure , myeloid leukemia

Target therapy can cause various cardiovascular complications. The aim of this study was to evaluate the burden of cardiovascular complications related to treatment with anti-BCR-ABL tyrosine kinase inhibitors (TKIs) and to determine if there are differences between the latest- and first-generation TKIs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research